Clinical Trial News and Research

RSS

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

11 Mar 2011

FDA approves Lantheus Medical Imaging's SPA for flurpiridaz F-18 Phase 3 trial in coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design and planned analysis of a Phase 3 clinical trial for the assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of flurpiridaz F-18 in patients with suspected or known coronary artery disease (CAD).

11 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.

11 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

First U.S. catheter ablation procedure for treatment of AF performed at Mount Sinai

The Mount Sinai Medical Center has become the first hospital in the United States to perform a cardiac catheterization procedure using the TactiCath force-sensing ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation, or periodic rapid and irregular heartbeats.

11 Mar 2011

New North American survey highlights impact of more complex clinical trials

A new North American survey of 500+ clinical research site professionals documents the impact of more kinds of, and more complex, clinical trials. The survey focused on 3-year trial trends and found key challenges in subject recruitment/retention and tracking and reporting data.

11 Mar 2011

New MEAL study can stop or delay prostate cancer progression

The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.

11 Mar 2011

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71, which causes hand, foot, and mouth disease.

10 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

Stem cells derived from a patient's own bone marrow were safely used in pediatric patients with traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

10 Mar 2011

Avinger completes patient enrollment in CONNECT trial to treat CTOs linked with PAD

Avinger, Inc., medical device manufacturer of innovative, multi-functional catheters for treating patients with peripheral artery disease, announced that it has successfully completed enrollment in its CONNECT clinical trial.

10 Mar 2011

Columbia fourth quarter total net revenues increase 74% to $14.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2010.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

A top medical researcher at Barrow Neurological Institute at St. Joseph's Hospital in Phoenix, Arizona, has launched a clinical trial to pinpoint brain activity in depressed people by using scientifically designed sad and heartrending photos and music.

10 Mar 2011

U-M participates in national trial for alternative approach to open heart surgery for severe aortic stenosis

The University of Michigan Cardiovascular Center, a leader in heart valve replacement, will participate in a national clinical trial to offer patients a less invasive approach to replacing diseased aortic valves.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011